Otherwise, mature NGF has been continuously tested for its use in neurological diseases and made good progress; however, in the central neural system, NGF therapy still confronted the big challenge of vector mistargeting and blood-brain barrier delivery. The gene discussed is NGF; the disease is nervous system disorder.